ESTRO 2024 - Abstract Book

S970

Clinical - CNS

ESTRO 2024

No clinical or molecular factors were found to have a statistically significant impact on PFS.

Median OS was 72,94 months (95% CI: 49,540-127) and only KPS had a significant influent on OS (P = 0,0215) (Fig. 2)

No correlation on OS was found between patients with one or more recurrences compared to those without any recurrence.

Conclusion:

KPS remains a strong prognosticator even in long-term GBM survivors. Freedom from recurrence did not have significant impact on patients' outcome in our study. Larger study are warranted to identify biomarkers that could lead to an early identification of these small but significant cohort of patients.